97964-56-2 Usage
Uses
Used in Pharmaceutical Industry:
LORGLUMIDE is used as a cholecystokinin receptor antagonist for its ability to block CCK-mediated muscle contraction, pancreatic growth, and secretion. This makes it a potential candidate for the development of treatments targeting gastrointestinal disorders and other conditions related to CCK receptor activity.
Used in Medical Research:
In the field of medical research, LORGLUMIDE is used as a tool to study the role of cholecystokinin receptors in various physiological processes. Its antagonistic properties allow researchers to investigate the effects of blocking CCK receptors, leading to a better understanding of their function and potential therapeutic applications.
Used in Synthesis of Lorglumide Sodium Salt:
LORGLUMIDE serves as an intermediate in the synthesis of Lorglumide Sodium Salt (L469910), a nonpeptidic antagonist of the CCK A receptor. LORGLUMIDE is valuable for the development of pharmaceuticals targeting the CCK A receptor, with potential applications in treating gastrointestinal disorders and other related conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 97964-56-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,9,6 and 4 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 97964-56:
(7*9)+(6*7)+(5*9)+(4*6)+(3*4)+(2*5)+(1*6)=202
202 % 10 = 2
So 97964-56-2 is a valid CAS Registry Number.
InChI:InChI=1/C22H32Cl2N2O4.Na/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16;/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28);/q;+1/p-1
97964-56-2Relevant academic research and scientific papers
New glutamic and aspartic derivatives with potent CCK-antagonistic activity
Makovec,Chiste,Bani,et al.
, p. 9 - 20 (2007/10/02)
New derivatives of aspartic and glutamic acid were synthesized and evaluated in vitro and in vivo for anti-CCK activity on the guinea pig gallbladder. The anti-CCK activity of some 4-benzamido-glutaramic acid derivatives was a hundred times greater than that of proglutamide, the model compound, and they have been selected for further studies.
